posted on 2021-05-11, 19:27authored byPriyamvada M. Pitale, Irina V. Saltykova, Yvonne Adu-Agyeiwaah, Sergio Li Calzi, Takashi Satoh, Shizuo Akira, Oleg Gorbatyuk, Michael E. Boulton, Machelle T. Pardue, W. Timothy Garvey, Mohammad Athar, Maria B. Grant, Marina S. Gorbatyuk
The current
understanding of molecular pathogenesis of diabetic retinopathy does not
provide a mechanistic link between early molecular changes and the subsequent
progression of the disease. In this study, we found that human diabetic retinas
overexpressed TRIB3 and investigated the role of TRIB3 in diabetic retinal pathobiology
in mice. We discovered that TRIB3 controlled major molecular events in early
diabetic retinas via HIF1α-mediated regulation of retinal glucose flux,
reprograming cellular metabolism, and governing inflammatory gene expression.
These early molecular events further defined the development of neurovascular
deficit observed in mice with diabetic retinopathy. TRIB3 ablation in
STZ-induced mouse model led to significant RGC survival and functional
restoration accompanied by a dramatic reduction in pericyte loss and acellular
capillary formation. Under hypoxic conditions, TRIB3 contributed to advanced
proliferative stages by significant upregulation of GFAP and VEGF expression,
thus controlling gliosis and aberrant vascularization in OIR mouse retinas. Overall,
our data reveal that TRIB3 is a master regulator of diabetic retinal
pathophysiology that may accelerate the onset and progression of diabetic
retinopathy to proliferative stages in humans and present TRIB3 as a
potentially novel therapeutic target for diabetic retinopathy.
Funding
This work was supported by the National Eye Institute, grants RO1 EY027763, R21YE031103.